2. (Amended) The [composition] particles of Claim 1 wherein the aerodynamic diameter of the particles is between approximately one and three microns.

3. (Amended) The [composition] particles of Claim 1 wherein at least 50% of the particles have a mean diameter between 5 μm and 15 μm and a tap density less than 0.1 g/cm^3.

11. (Amended) The [composition] particles of Claim 1 wherein the [therapeutic] agent is selected from the group consisting of proteins, polysaccharides, lipids, nucleic acids and combinations thereof.

12. (Amended) The [composition] particles of Claim 1 wherein the [therapeutic] agent is selected from the group consisting of nucleotides and oligonucleotides.

13. (Amended) The [composition] particles of Claim [11] 1 wherein the [therapeutic] agent is selected from the group consisting of insulin, calcitonin, leuprolide and albuterol.

14. (Amended) The [composition] particles of Claim 1 wherein the surfactant is selected from the group consisting of a fatty acid, a phospholipid, and a block copolymer.

15. (Amended) The [composition] particles of Claim 14 wherein the surfactant is a phosphoglyceride.

16. (Amended) The [composition] particles of Claim 14 wherein the surfactant is L-α-phosphatidylcholine dipalmitoyl.

17. (Amended) The [composition] particles of Claim 1 wherein the agent is a charged species and is present as a complex with an oppositely charged species.

18. (Amended) The [composition] particles of Claim 17 wherein the agent is hydrophilic and is present as a complex with a hydrophobic moiety.

19. (Twice amended) A method for drug delivery to the pulmonary system comprising:

administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles consisting of a therapeutic, prophylactic or diagnostic agent and a [molecule] material selected from the group consisting of surfactant and a molecule having a charge opposite to the charge of [the therapeutic] said agent and forming a complex thereto, and combinations thereof,

wherein the particles have a tap density less than 0.4 g/cm^3, [and] a mean diameter between 5 μm and 30 μm [effective to yield] and an aerodynamic diameter of [the particles of] between approximately one to five microns.

28. (Amended) The method of Claim 19 wherein [the therapeutic] said agent is selected from the group consisting of proteins, polysaccharides, lipids, nucleic acids and combinations thereof.

29. (Amended) The method of Claim 19 wherein [the therapeutic] said agent is selected from the group consisting of nucleotides and oligonucleotides.

30. (Amended) The method of Claim [28] 19 wherein [the therapeutic] said agent is selected from the group consisting of insulin, calcitonin, leuprolide and albuterol.

Please add Claim 39 as follows:

39. The method of Claim 19 where the particles are administered in combination with a pharmaceutically acceptable carrier for administration to the respiratory tract.

REMARKS

Entry of the Supplemental Amendment is respectfully requested.

A reference has been made at page 1 of the Specification to Applicants' co-pending U.S. applications. A supplemental declaration reflecting the claim for priority will be filed when available.